Because of potential adverse side effects of bortezomib (BORT) in imatinib-refractory CML patients, we designed a transferrin (Tf)-targeted liposomal formulation (Tf-L-BORT) for BORT delivery. This evidence concerns the gene TF and chronic myelogenous leukemia, BCR-ABL1 positive.